Nonribosomal peptide evolution runs on selection chance and biased gene swaps

A study of nonribosomal peptide evolution reports that three forces shape the peptides bacteria assemble on enzyme production lines: natural selection, plain chance and a bias in which pieces of genes recombine. Researchers in Marburg traced one such peptide family across many bacterial strains and counted 49 distinct versions. The paper appeared in Nature Ecology and Evolution on 21 October 2026. It matters for antibiotics, because many are built by the same machinery.

How bacteria assemble peptides without ribosomes

Most proteins are made on ribosomes, which read messenger RNA and add one amino acid at a time. Nonribosomal peptides take a different route. Large enzymes called nonribosomal peptide synthetases work as production lines, and each module selects, activates and attaches one building block before passing the growing chain along. Because modules can draw on unusual building blocks, the products are chemically varied, and several important antibiotics come from such lines. The group of Helge Bode at the Max Planck Institute for Terrestrial Microbiology works on redesigning these enzymes to make new drug candidates, which is easier if you know how nature has already rearranged them.

Studying nonribosomal peptide evolution is hard with the usual tools. Ordinary genes change mostly through single letter mutations, and standard statistical tests for selection are built around those point changes. Synthetase genes instead exchange whole stretches of sequence by recombination, so a module can be replaced wholesale by one from another gene. Every exchange scrambles part of the historical record, and Georg Hochberg of the University of Marburg summed up the problem by saying that each recombination event overwrites a piece of the past. The team combined family trees that allow for recombination, reconstruction of ancestral sequences, and statistics on past exchanges. Readers new to bacterial peptide drugs can start with a lasso shaped antibiotic found in a garden soil sample.

Rebuilding the history of one enzyme

The model system was the GameXPeptide family, made by Xenorhabdus and Photorhabdus bacteria. These microbes live inside nematode worms that enter insect larvae, and the peptides act during that infection, so insect resistance gives selection something to push against. The enzyme responsible has five modules, few enough for a complete history to be rebuilt. Doing so meant restoring roughly 15,000 base pairs of ancestral sequence, assembling them into a working gene and expressing it in laboratory bacteria. The reconstruction turned up 49 distinct compounds in the family, among them shortened ring shaped peptides of four building blocks and an extended one of six.

The reconstruction turned up 49 distinct compounds in the family, among them shortened ring shaped peptides of four building blocks and an extended one of six.

Several lineages that had diverged long before arrived at identical or nearly identical structures, a pattern known as convergence. To test whether selection was behind the diversity, the team used exchanges that leave the product unchanged as a neutral yardstick, then asked where the exchanges that do alter the sequence land. Those fell on the regions that choose building blocks far more often than the yardstick predicts, which points to positive selection. Laboratory assays with four insect species supported the idea that the differences matter biologically, since the variants acted on the four species with different efficiencies. Sebastian Kaiser, the first author, told Phys.org that he was completely surprised by how many variants exist.

Chance and a bias in which modules recombine

Selection was not the whole story. A large share of the diversity looks like the random fixation of variants that offer no advantage, the process known as genetic drift. The bacteria's life cycle makes this plausible. Each nematode is colonised at first by only a handful of bacterial cells, and such bottlenecks keep populations small, which magnifies the role of chance. The third force is a bias in recombination itself. Exchanges happen preferentially between modules whose sequences already resemble one another, so the enzymes keep reusing building blocks that are present in their own gene cluster rather than reaching for the wider repertoire available in principle.

That bias is self reinforcing, because each exchange makes the modules in a cluster more alike and so more likely to recombine again. The authors suggest this may explain the convergence they saw: the same variants reappear partly because they are easy to produce, not necessarily because they work better. It is a careful claim, and the paper hedges it. Hochberg described the difficulty of ordering the events as playing five dimensional chess, which gives a sense of how much inference sits between the data and the conclusion. Work on antibiotic peptides from unusual microbes shows how much chemical space remains unexplored.

What this does not deliver

No new medicine comes out of this study. It describes the history of one enzyme family in one group of bacteria, tested against four insect species in the laboratory, and the framework has not yet been applied to the synthetases behind antibiotics used in hospitals. The evidence for drift is statistical and rests on a model of how these bacteria colonise their hosts rather than on direct measurement of population sizes in the field. The convergence explanation is offered as a possibility, not a demonstration. Full details sit behind a subscription, so our account draws on the abstract, the author list and the institute's own description of the work.

The practical hope is modest and worth stating in the authors' terms. Bode told Phys.org that the framework could help uncover new antibiotics that overcome existing resistance, on the reasoning that past recombination events may have produced active variants nobody has looked for. He also suggested applying the same approach to polyketide synthases, a related family behind other clinically relevant natural products. Kaiser said the field is only at the beginning of understanding how natural products evolve. For now the contribution of this work to nonribosomal peptide evolution is methodological, and the drug candidates it may point to remain hypothetical.

Conclusion

This account of nonribosomal peptide evolution separates three forces that shape bacterial peptides: selection on the regions that choose building blocks, drift amplified by small founding populations, and a recombination bias that keeps reusing familiar parts. The conclusions come from one enzyme family, mostly from sequence analysis with laboratory assays in insects. No medicine follows yet, but the method gives engineers a clearer map of what nature has already tried.

Source Kaiser S, Hochberg GKA, Bode HB and colleagues. Drift, selection and recombination bias drive the evolution of a non-ribosomal peptide. Nature Ecology and Evolution, published online 21 October 2026. DOI 10.1038/s41559-026-03214-y

Amino Weekly reports research. It is not medical advice and never gives doses.